Triamcinolone Acetonide (triamcinolone acetonide)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Triamcinolone is a synthetic glucocorticoid.

Triamcinolone is used principally as an anti-inflammatory or immunosuppressant agent. Because it has virtually no mineralocorticoid properties, the drug is inadequate alone for the management of adrenocortical insufficiency. If triamcinolone is used in the treatment of this condition, concomitant therapy with a mineralocorticoid is also required.

Generic name: triamcinolone acetonide
Pronunciation: (TRYE-am-SIN-oh-lone)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Triamcinolone Acetonide

Intelligence content is not available yet.

Indications

The following indications are listed for Triamcinolone Acetonide:

  • Acute Gouty Arthritis
  • Alopecia Areata
  • Bursitis
  • Discoid Lupus Erythematosus
  • Epicondylitis
  • Ganglion Cyst
  • Granuloma Annulare
  • Keloid
  • Lichen Planus
  • Lichen Simplex Chronicus
  • Necrobiosis Lipoidica Diabeticorum
  • Plaque Psoriasis
  • Rheumatoid Arthritis
  • Subacute Bursitis
  • Synovitis Due To Osteoarthritis
  • Tenosynovitis

Also known as: Acute Articular Gout, Acute Gout Attack, Acute Gout Flare, Acute Uratic Arthritis, Areata Alopecia, Arthritis Deformans, Arthrosis Deformans, Benign Cystic Mucinous Tumor, Cheloids, Circumscribed Neurodermatitis, Ganglion, Ganglionic Cyst, Keloid Scar, Lichen Annularis, Lipoidica Diabeticorum Necrobiosis, Myxoid Cyst, Nodose Rheumatism, Rheumatic Arthritis, Rheumatic Gout, Synovitis Due To Oa, Synovitis With Osteoarthritis, Tendinous Synovitis, Tendosynovitis, Tendovaginitis, Tenontolemmitis, Tenontothecitis, Tenovaginitis, Vidal's Disease.

Dosing

The route of administration and dosage of triamcinolone and its derivatives depend on the condition being treated and the response of the patient. IM therapy is generally reserved for patients who are not able to take the drug orally. Dosage for infants and children should be based on the severity of the disease and the response of the patient rather than on strict adherence to dosage indicated by age, body weight, or body surface area. After a satisfactory response is obtained, dosage should be decreased in small decrements to the lowest level that maintains an adequate clinical response, and the drug should be discontinued as soon as possible. Patients should be continually monitored for signs that indicate dosage adjustment is necessary, such as remissions or exacerbations of the disease and stress (surgery, infection, trauma). One manufacturer recommends that an alternate-day dosage regimen be considered when long-term oral triamcinolone therapy is necessary. However, most authorities state that only methylprednisolone, prednisolone, and prednisone have been proven to be suitable for alternate-day glucocorticoid therapy. Following long-term therapy, triamcinolone should be withdrawn gradually.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data